Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XERS Xeris Pharmaceuticals Inc

Market Closed 12-20 16:00:00 EST

3.49

+0.08

+2.35%

盘后3.50

+0.01+0.29%

19:56 EST

High3.57	Low3.35	Vol1.52M
Open3.35	D1 Closing3.41	Amplitude6.42%
Mkt Cap520.29M	Tradable Cap497.25M	Total Shares149.08M
T/O5.31M	T/O Rate1.07%	Tradable Shares142.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"XERS","market":"US","secType":"STK","nameCN":"Xeris Pharmaceuticals Inc","latestPrice":3.49,"timestamp":1734728400000,"preClose":3.41,"halted":0,"volume":1524094,"hourTrading":{"tag":"盘后","latestPrice":3.5,"preClose":3.49,"latestTime":"19:56 EST","volume":53010,"amount":185102.9631,"timestamp":1734742560182},"delay":0,"floatShares":142479477,"shares":149081461,"eps":-0.438272,"marketStatus":"Market Closed","change":0.08,"latestTime":"12-20 16:00:00 EST","open":3.35,"high":3.569,"low":3.35,"amount":5307009.919869,"amplitude":0.064223,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.438272,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":3.41,"preHourTrading":{"tag":"盘前","latestPrice":3.38,"preClose":3.41,"latestTime":"09:28 EST","volume":334,"amount":1129.020066,"timestamp":1734704938025},"postHourTrading":{"tag":"盘后","latestPrice":3.5,"preClose":3.49,"latestTime":"19:56 EST","volume":53010,"amount":185102.9631,"timestamp":1734742560182},"volumeRatio":0.8765422267967979,"impliedVol":0.8313,"impliedVolPercentile":0.5476},"requestUrl":"/m/hq/s/XERS","defaultTab":"news","newsList":[{"id":"2486707908","title":"Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486707908","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486707908?lang=en_us&edition=fundamental","pubTime":"2024-11-26 20:00","pubTimestamp":1732622400,"startTime":"0","endTime":"0","summary":"CHICAGO, November 26, 2024----Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 at 8:00am Eastern Time.Xeris  is a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev, for the treatment of endogenous Cushing’s syndrome; Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs to bring new products forward using its proprietary formulation technology platforms, XeriSol a","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CCir5Ufb._3KcIzFXUfwxQ--~B/aD0yNzQ7dz04MDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4735c50a5c2fab9e149027201772825d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CCir5Ufb._3KcIzFXUfwxQ--~B/aD0yNzQ7dz04MDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4735c50a5c2fab9e149027201772825d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-participate-piper-sandler-36th-120000879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4137","HCSG","BK4007","XERS"],"gpt_icon":0},{"id":"2484163881","title":"Analysts Expect Breakeven For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Before Long","url":"https://stock-news.laohu8.com/highlight/detail?id=2484163881","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484163881?lang=en_us&edition=fundamental","pubTime":"2024-11-17 20:57","pubTimestamp":1731848261,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Xeris Biopharma Holdings, Inc.'s  future prospects. Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company’s loss has recently broadened since it announced a US$62m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$63m, moving it further away from breakeven. As path to profitability is the topic on Xeris Biopharma Holdings' investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.View our latest analysis for Xeris Biopharma Holdings","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/analysts-expect-breakeven-xeris-biopharma-125741335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","QID","PSQ","IE00BGHQF748.EUR","NDAQ","SQQQ","BK4112",".IXIC","LU2210149790.SGD","BK4585","LU2095319765.USD","IE00B64PRP62.GBP","TQQQ","IE00B3QW5Z07.USD","NQmain","IE00BKPKM429.USD","BK4007","MNQmain","LU2210150020.SGD","XERS","QLD"],"gpt_icon":1},{"id":"2482873924","title":"Xeris Biopharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2482873924","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482873924?lang=en_us&edition=fundamental","pubTime":"2024-11-11 23:39","pubTimestamp":1731339540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XERS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2024 10:39 ET (15:39 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"gpt_icon":0},{"id":"1170797516","title":"Stock Track | Xeris Pharma Plunges in Pre-Market on Analyst Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=1170797516","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170797516?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:28","pubTimestamp":1731328096,"startTime":"0","endTime":"0","summary":"Shares of Xeris Pharmaceuticals Inc.  plummeted over 7% in pre-market trading on Friday, November 11th, 2024, following a downgrade by Piper Sandler analyst David Amsellem.Amsellem lowered his rating on Xeris Biopharma from Overweight to Neutral, while maintaining his price target of $3 per share. The downgrade came after the company's third-quarter earnings report, though Amsellem did not provide specific details regarding the rationale behind his decision.The stock had been trading around $3.4","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | Xeris Pharma Plunges in Pre-Market on Analyst Downgrade","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["XERS"],"gpt_icon":0},{"id":"2482378330","title":"Piper Sandler Downgrades Xeris Biopharma to Neutral From Overweight, $3 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2482378330","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482378330?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:25","pubTimestamp":1731327925,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings (XERS) has an average rating of Buy and price targets ranging from $3 to $6.60, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and economic ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XERS"],"gpt_icon":0},{"id":"2482205155","title":"Xeris Biopharma downgraded to Neutral from Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2482205155","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482205155?lang=en_us&edition=fundamental","pubTime":"2024-11-11 18:10","pubTimestamp":1731319844,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst David Amsellem downgraded Xeris Biopharma (XERS) to Neutral from Overweight with an unchanged price target of $3, post the Q3...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-downgraded-to-neutral-from-overweight-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-downgraded-to-neutral-from-overweight-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2482289672","title":"Xeris Biopharma Holdings Inc : Piper Sandler Cuts to Neutral From Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2482289672","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482289672?lang=en_us&edition=fundamental","pubTime":"2024-11-11 12:47","pubTimestamp":1731300423,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nFWN3MF2O6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2482417473","title":"Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2482417473","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482417473?lang=en_us&edition=fundamental","pubTime":"2024-11-09 15:06","pubTimestamp":1731135971,"startTime":"0","endTime":"0","summary":"Total Revenue: $54.3 million, a 12% increase compared to the prior year.Net Product Revenue: $52.9 million, a 27% increase compared to the prior year.Year-to-Date Net Product Revenue: $139.6 million, a 26% increase compared to the prior year.Year-to-Date Total Revenue: $143 million, a 20% increase compared to the prior year.Recorlev Net Revenue: $17.7 million for the quarter, more than doubling compared to the prior year.Gvoke Net Revenue: $22.9 million for the quarter, a 29% increase compared to the prior year.Keveyis Net Revenue: $12.2 million for the quarter.Cash Position: Over $69 million at the end of the quarter.Cost of Goods Sold: 25.7% of total product revenue for the quarter.Research and Development Expenses: $5.9 million for the third quarter.Selling, General and Administrative Expenses: $45 million for the quarter, a 21% increase compared to the prior year.Revenue Guidance: Raised to $198 to $202 million for the year.GuruFocus has detected 5 Warning Signs with XERS.Xeris Bio","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZW00nU381I61PSodKqgEIg--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7d017290c2a9f1a3b0b5db2993e4f886","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZW00nU381I61PSodKqgEIg--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7d017290c2a9f1a3b0b5db2993e4f886"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-holdings-inc-xers-070611455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XERS"],"gpt_icon":0},{"id":"2482048915","title":"Xeris Biopharma Holdings Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2482048915","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482048915?lang=en_us&edition=fundamental","pubTime":"2024-11-09 00:24","pubTimestamp":1731083054,"startTime":"0","endTime":"0","summary":"* Xeris Biopharma Holdings Inc    reported a quarterly adjusted loss of 11 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"gpt_icon":0},{"id":"1168315264","title":"Stock Track | Xeris Pharmaceuticals Soars on Q3 Beat, Raised 2024 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1168315264","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168315264?lang=en_us&edition=fundamental","pubTime":"2024-11-08 23:05","pubTimestamp":1731078307,"startTime":"0","endTime":"0","summary":"Shares of Xeris Pharmaceuticals Inc  soared over 5% in pre-market trading on November 8, 2024 after the biopharmaceutical company reported better-than-expected third quarter results and raised its full-year revenue guidance.For the third quarter, Xeris posted total revenue of $54.3 million, exceeding analysts' estimates of $51.4 million. The solid top-line growth was driven by strong demand for the company's key products - Gvoke, Recorlev and Keveyis.Gvoke, the ready-to-use glucagon for severe h","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["XERS"],"gpt_icon":0},{"id":"2481954483","title":"Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481954483","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481954483?lang=en_us&edition=fundamental","pubTime":"2024-11-08 22:30","pubTimestamp":1731076210,"startTime":"0","endTime":"0","summary":"Xeris Biopharma  reported $54.27 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 12.3%. EPS of -$0.06 for the same period compares to -$0.09 a year ago.The reported revenue represents a surprise of +5.09% over the Zacks Consensus Estimate of $51.64 million. With the consensus EPS estimate being -$0.09, the EPS surprise was +33.33%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Here is how Xeris Biopharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:. Product Revenue- Gvoke: $22.94 million versus $22.97 million estimated by four analysts on average.Product Revenue- Keveyis: $12.19 million versus $12.50 million estimated by four ana","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UACuRym2G7Sc_7yqOtSLVQ--~B/aD0yMzUxO3c9MzAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/zacks.com/c65fb4556b91b6c9dc83e4eff25fede0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UACuRym2G7Sc_7yqOtSLVQ--~B/aD0yMzUxO3c9MzAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/zacks.com/c65fb4556b91b6c9dc83e4eff25fede0"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-xers-q3-earnings-143010959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XERS"],"gpt_icon":0},{"id":"2481104926","title":"Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481104926","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481104926?lang=en_us&edition=fundamental","pubTime":"2024-11-08 21:10","pubTimestamp":1731071403,"startTime":"0","endTime":"0","summary":"Xeris Biopharma  came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this company would post a loss of $0.11 per share when it actually produced a loss of $0.10, delivering a surprise of 9.09%.Xeris Biopharma , which belongs to the Zacks Medical - Drugs industry, posted revenues of $54.27 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 5.09%. This compares to year-ago revenues of $48.32 million. The company has topped consensus revenue estimates two times over the last four quarters.Xeris Biopharma shares have added about 43% since the beginning of the year versus the S&P 500's gain of 25.2%.While Xeris Biopharma has outperformed the market so far this year, the question that comes to invest","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/132juehTNIyEUn7pK7.GPA--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/132juehTNIyEUn7pK7.GPA--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-xers-reports-q3-131003367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XERS"],"gpt_icon":0},{"id":"1181652532","title":"Stock Track | Xeris Pharmaceuticals Soars 6% Pre-Market on Q3 Beat, Raised Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1181652532","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181652532?lang=en_us&edition=fundamental","pubTime":"2024-11-08 21:03","pubTimestamp":1731070995,"startTime":"0","endTime":"0","summary":"Xeris Pharmaceuticals Inc  shares soared over 6% in pre-market trading on Wednesday after the company reported better-than-expected third-quarter results and raised its full-year revenue guidance. The biopharmaceutical firm posted a Q3 revenue of $54.3 million, exceeding analysts' estimates of $51.4 million, driven by strong demand for its products Gvoke, Recorlev and Keveyis.Xeris saw robust growth across its key products in Q3. Gvoke net revenue jumped 29% year-over-year to $22.9 million on ri","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["XERS"],"gpt_icon":0},{"id":"2481171536","title":"BRIEF-Xeris Biopharma Reports Q3 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2481171536","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481171536?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:26","pubTimestamp":1731068817,"startTime":"0","endTime":"0","summary":"Nov 8  - Xeris Biopharma Holdings Inc   :   * XERIS BIOPHARMA REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS   * XERIS BIOPHARMA HOLDINGS: RAISES FY GUIDANCE OF TOTAL NET REVENUE TO $198 MILLION - $202MLN & TIGHTENS YEAR-END CASH TO $68MLN - $72MLN   * XERIS BIOPHARMA HOLDINGS: CASH, CASH EQUIVALENTS, & SHORT-TERM INVESTMENTS AT SEPT 30, 2024 WAS $69.4 MILLIONSource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2481920179","title":"Xeris Pharmaceuticals GAAP EPS of -$0.11 misses by $0.02, revenue of $54.3M beats by $2.87M","url":"https://stock-news.laohu8.com/highlight/detail?id=2481920179","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481920179?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:11","pubTimestamp":1731067886,"startTime":"0","endTime":"0","summary":"Xeris Pharmaceuticals press release  (NASDAQ:XERS): Q3  GAAP EPS of -$0.11  misses by $0.02.\nRevenue of $54.3M (+12.4% Y/Y)  beats by $2.87M.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4265158-xeris-pharmaceuticals-gaap-eps-of-0_11-misses-0_02-revenue-of-54_3m-beats-2_87m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["XERS"],"gpt_icon":0},{"id":"2481717951","title":"Xeris Biopharma: Q3 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2481717951","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481717951?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:10","pubTimestamp":1731067816,"startTime":"0","endTime":"0","summary":"CHICAGO  — CHICAGO  — Xeris Biopharma Holdings, Inc.  on Friday reported a loss of $15.7 million in its third quarter.On a per-share basis, the Chicago-based company said it had a loss of 11 cents. Losses, adjusted for non-recurring costs, came to 6 cents per share.The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 9 cents per share.The company posted revenue of $54.3 million in the period, also topping Street forecasts. Five analysts surveyed by Zacks expected $51.6 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-q3-earnings-snapshot-121016002.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XERS"],"gpt_icon":0},{"id":"2481764711","title":"Xeris Biopharma Raises Its 2024 Revenue Guidance To $198M-$202M From The Previous Guidance Of $190M-$200M Versus Consensus Of $193.403M, Tightens Year-End Cash To $68M-$72M","url":"https://stock-news.laohu8.com/highlight/detail?id=2481764711","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481764711?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:07","pubTimestamp":1731067671,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Raises Its 2024 Revenue Guidance To $198M-$202M From The Previous Guidance Of $190M-$200M Versus Consensus Of $193.403M, Tightens Year-End Cash To $68M-$72M","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/24/11/41840685/xeris-biopharma-raises-its-2024-revenue-guidance-to-198m-202m-from-the-previous-guidance-of-190m-","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"gpt_icon":0},{"id":"2481176947","title":"Xeris Biopharma Holdings Q3 2024 Adj EPS $(0.06) Beats $(0.09) Estimate, Sales $54.27M Beat $51.43M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481176947","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481176947?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:03","pubTimestamp":1731067386,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 33.33 percent.  The company reported quarterly sales of $54.27 million which","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41840313/xeris-biopharma-holdings-q3-2024-adj-eps-0-06-beats-0-09-estimate-sales-54-27m-beat-51-43m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Xeris Biopharma Holdings Q3 2024 Adj EPS $(0.06) Beats $(0.09) Estimate, Sales $54.27M Beat $51.43M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"gpt_icon":0},{"id":"2481176874","title":"BRIEF-Xeris Biopharma Q3 Net Income USD -15.738 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2481176874","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481176874?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:00","pubTimestamp":1731067245,"startTime":"0","endTime":"0","summary":"BRIEF-Xeris Biopharma Q3 Net Income USD -15.738 Million\n\n\nNov 08 (Reuters) - Xeris Biopharma Q3 basic EPS USD -0.11.\n\nQ3 operating income USD -12.893 million\nQ3 product revenue USD 52.861 million vs. IBES estimate USD 51.4 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nPLX4151E8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2481766771","title":"Xeris Biopharma Holdings: Raises FY Guidance of Total Net REV to $198 Mln - $202Mln & Tightens Year-End Cash to $68Mln - $72Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2481766771","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481766771?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:00","pubTimestamp":1731067201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nTUA80V1Y0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XERS","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xerispharma.com","stockEarnings":[{"period":"1week","weight":0.064},{"period":"1month","weight":0.1405},{"period":"3month","weight":0.1911},{"period":"6month","weight":0.654},{"period":"1year","weight":0.6619},{"period":"ytd","weight":0.4851}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.091365},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.026041},{"month":3,"riseRate":0.5,"avgChangeRate":-0.107706},{"month":4,"riseRate":0.5,"avgChangeRate":0.063543},{"month":5,"riseRate":0.666667,"avgChangeRate":0.186811},{"month":6,"riseRate":0.5,"avgChangeRate":-0.069518},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.024057},{"month":8,"riseRate":0.571429,"avgChangeRate":0.160809},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.078859},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.032117},{"month":11,"riseRate":0.571429,"avgChangeRate":0.00843},{"month":12,"riseRate":0.571429,"avgChangeRate":0.050125}],"exchange":"NASDAQ","name":"Xeris Pharmaceuticals Inc","nameEN":"Xeris Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xeris Pharmaceuticals Inc,XERS,Xeris Pharmaceuticals Inc股票,Xeris Pharmaceuticals Inc股票老虎,Xeris Pharmaceuticals Inc股票老虎国际,Xeris Pharmaceuticals Inc行情,Xeris Pharmaceuticals Inc股票行情,Xeris Pharmaceuticals Inc股价,Xeris Pharmaceuticals Inc股市,Xeris Pharmaceuticals Inc股票价格,Xeris Pharmaceuticals Inc股票交易,Xeris Pharmaceuticals Inc股票购买,Xeris Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction